- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03267901
Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome
Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome in South Korea
Investigators planed to conduct a randomized, controlled, crossover trial to examine the effects of daily walnuts intake among Korean subjects with metabolic syndrome. Primary objective of this study was to investigate the effects of daily walnut intake on changes of metabolic syndrome indices in Koreans with metabolic syndrome age over 30 years old. This study was consisted of four periods: run-in, first intervention, wash-out, and second intervention phases. As 16 weeks of first intervention period began after the run-in phase, the subjects were randomly assigned into one of two groups: walnut group and control group. Participants in walnut group consumed 45 grams of walnuts on a daily basis and participants in control group were provided iso-caloric white bread for first 16 weeks. After the first intervention and wash-out period (6 weeks), second intervention which is crossover of first intervention was started during the next 16 weeks. Anthropometric measurements and biochemical analyses were done at the beginning and the end of each intervention (0, 16, 22, and 38 weeks of trial). Habitual diet was randomly observed using 3-day diet record once during each phase.
Investigators expected to evaluate 1)effects of walnut ingestion on reverting metabolic syndrome to normal status especially by reducing waist circumference and improving serum levels of triglyceride and high-density lipoprotein, 2)beneficial effects of daily walnut consumption on changes of body composition in the subjects with metabolic syndrome, and 3)regulatory effects of daily walnut intake on inflammatory markers and diabetic markers.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 07327
- ICAN Nutrition Education and Research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria: at least three out of five metabolic syndrome components
- waist circumference (WC) >90 cm for men and >80 cm for women
- hypertension (DBP ≥85 and <110 mm Hg)
- hyperglycemia (≥100 mg/dL)
- elevated plasma TG concentrations (≥150 mg/dL)
- decreased plasma HDL-C concentrations (<40 mg/dL for men and <50 mg/dL for women)
Exclusion Criteria:
- the presence of morbid obesity (BMI ≥40)
- the use of any medication for the control of blood pressure, glucose, or lipid metabolism
- a medical history of hypocaloric diet consumption within the past year
- gastrointestinal tract disorders
- post-menopausal women
- smokers
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Walnut-Control
|
45 g of walnut / iso-caloric white bread
|
|
Eksperimentell: Control-Walnut
|
45 g of walnut / iso-caloric white bread
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
changes of waist circumference
Tidsramme: after 16 weeks of daily walnut consumption
|
Waist circumferences (cm) were obtained at the midpoint between the lowest rib and the iliac crest and rounded to the nearest 0.1 cm after inhalation and exhalation.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood triglyceride level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum triglycerides (mg/dL) levels were measured by an enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood high-density lipoprotein cholesterol levels
Tidsramme: after 16 weeks of daily walnut consumption
|
High density lipoprotein cholesterol (mg/dL) levels were determined by a homogeneous enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood pressure
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood pressure (mmHg) was measured on the right arm using an up-load blood pressure monitor with participants in a comfortably seated position after at least a 5-minute rest.
|
after 16 weeks of daily walnut consumption
|
|
changes of blood glucose level
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood glucose levels (mg/dL) were measured using blood glucose monitor and test stripts from the finger tip.
|
after 16 weeks of daily walnut consumption
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
changes of total cholesterol level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum total cholesterol levels (ml/dL) were measured by an enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum apolipoprotein B level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum apolipoprotein B (ml/dL) was measured using a turbidimetric immunoassay.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum adiponectin level
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood adiponectin (ug/mL) levels were measured using ELISA.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum leptin level
Tidsramme: after 16 weeks of daily walnut consumption
|
Blood leptin (ug/mL) levels were measured using ELISA.
|
after 16 weeks of daily walnut consumption
|
|
changes of serum insulin level
Tidsramme: after 16 weeks of daily walnut consumption
|
Serum insulin (μU/mL) was measured with a commercially available kit, the ultrasensitive insulin ELISA kit using an Epoch microplate spectrophotometer.
|
after 16 weeks of daily walnut consumption
|
|
changes of low-density lipoprotein cholesterol level
Tidsramme: after 16 weeks of daily walnut consumption
|
Low-density lipoprotein cholesterol levels (ml/dL) were determined by a homogeneous enzymatic-colorimetric method.
|
after 16 weeks of daily walnut consumption
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CWC-2016-MetS
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metabolsk syndrom
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbeidspartnereHar ikke rekruttert ennåLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitt | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpania
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia
-
Tangram Therapeutics PlcRekrutteringFriske deltakere | MASH - Metabolic Dysfunction-Associated SteatohepatittStorbritannia
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittKina
-
Southern California Institute for Research and...Har ikke rekruttert ennåMASH - Metabolic Dysfunction-Associated Steatohepatitt
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittPakistan
-
University of Campania Luigi VanvitelliFullførtMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia
-
University of Campania Luigi VanvitelliFullførtKardiovaskulære hendelser | MASLD | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia
Kliniske studier på food
-
NYU Langone HealthNational Institute of Allergy and Infectious Diseases (NIAID)RekrutteringMatproteinindusert enterokolittsyndromForente stater
-
Ohio State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrutteringDiabetes mellitus, type 2 | Dårlig ernæring | MatmangelForente stater
-
The Miriam HospitalNational Institute of General Medical Sciences (NIGMS)AvsluttetBetennelse | Matusikkerhet | Fedme, barndom | Mental HelseForente stater
-
University of British ColumbiaFullført
-
NYU Langone HealthAmerican Heart AssociationFullført
-
Medical University of South CarolinaWW InternationalFullførtOvervekt | VekttapForente stater
-
Medical University of WarsawHar ikke rekruttert ennåEggallergi | Matallergi | HøneeggallergiPolen
-
Pacific Cancer CareFullført
-
International Food Policy Research InstituteHelen Keller International; Foreign Affairs, Trade and Development, CanadaFullførtAnemi | VeksthemningBurkina Faso
-
Mondelēz International, Inc.Cognitive Research CorporationFullført